Total Funding
58
42
Total FundingPost-IPO Equity raised
Growth Score
-2 pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
141169
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases.
Anders Hinsby: Chief Executive OfficerPast Role: Technical University of Denmark, Assistant Professor of Systems Biology
Thomas Kirkegaard Jensen: Chief Scientific Officer
About the Company
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).
Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
